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Strengths and limitations of this study
 ► Methodological advantages over previous studies, 
including a very large sample size, adjustment for 
a more comprehensive range of confounders, and 
the inclusion of non-fatal adverse cardiovascular 
events from hospital admission data and death reg-
istry data.
 ► Definition of prior major depressive disorder (MDD) 
history was based on International Classification of 
Diseases-10 Revision diagnostic criteria (rather than 
a score on a symptoms questionnaire) and our com-
posite definition of hypertension incorporated histo-
ry, current medication and objective blood pressure 
measurements.
 ► Although analyses were adjusted for a broad range 
of baseline factors (such as smoking status, body 
mass index, psychotropic medication use and diabe-
tes), we were unable to account for how these fac-
tors may have changed over the course of follow-up, 
or assess adherence to cardiovascular medications.
 ► Trained nurses interviewed UK Biobank participants, 
but the self-report nature of some of these data may 
represent a limitation.
 ► UK Biobank may have issues with respect to se-
lection biases. For example, individuals with more 
severe MDD may have been less likely to volunteer.
AbStrACt
Objectives To assess whether a history of major 
depressive disorder (MDD) in middle-aged individuals with 
hypertension influences first-onset cardiovascular disease 
outcomes.
Design Prospective cohort survival analysis using Cox 
proportional hazards regression with a median follow-
up of 63 months (702 902 person-years). Four mutually 
exclusive groups were compared: hypertension only (n=56 
035), MDD only (n=15 098), comorbid hypertension plus 
MDD (n=12 929) and an unaffected (no hypertension, no 
MDD) comparison group (n=50 798).
Setting UK Biobank.
Participants UK Biobank participants without 
cardiovascular disease aged 39–70 who completed 
psychiatric questions relating International Classification 
of Diseases-10 Revision (ICD-10) diagnostic criteria on a 
touchscreen questionnaire at baseline interview in 2006–
2010 (n=134 860).
Primary and secondary outcome measures First-
onset adverse cardiovascular outcomes leading to 
hospital admission or death (ICD-10 codes I20–I259, 
I60–69 and G45–G46), adjusted in a stepwise manner for 
sociodemographic, health and lifestyle features. Secondary 
analyses were performed looking specifically at stroke 
outcomes (ICD-10 codes I60–69 and G45–G46) and in 
gender-separated models.
results Relative to controls, adjusted HRs for adverse 
cardiovascular outcomes were increased for the 
hypertension only group (HR 1.36, 95% CI 1.22 to 1.52) 
and were higher still for the comorbid hypertension plus 
MDD group (HR 1.66, 95% CI 1.45 to 1.9). HRs for the 
comorbid hypertension plus MDD group were significantly 
raised compared with hypertension alone (HR 1.22, 95% 
CI 1.1 to 1.35). Interaction measured using relative excess 
risk due to interaction (RERI) and likelihood ratios (LRs) 
were identified at baseline (RERI 0.563, 95% CI 0.189 to 
0.938; LR p=0.0116) but not maintained during the follow-
up.
Limitations Possible selection bias in UK Biobank and 
inability to assess for levels of medication adherence.
Conclusions Comorbid hypertension and MDD conferred 
greater hazard than hypertension alone for adverse 
cardiovascular outcomes, although evidence of interaction 
between hypertension and MDD was inconsistent over 
time. Future cardiovascular risk prediction tools may 
benefit from the inclusion of questions about prior history 
of depressive disorders.
IntrODuCtIOn
By 2030, major depressive disorder (MDD) 
and cardiovascular disease (CVD) will be the 
two leading causes of disability worldwide.1 
MDD is associated with CVD and worse long-
term outcomes.2 To date, survival analysis 
in comorbid hypertension and MDD have 
focused on all-cause death3–5 CV death5 
or incorporated individuals with previous 
CVD,3–6 and have suggested a possible addi-
tive interaction between hypertension and 
MDD on survival.5 6 MDD is well known to 
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worsen post-CV event survival.6 7 The contribution on 
survival to first-onset CVD is less clear when MDD is strat-
ified by hypertension and no prior study has assessed 
comorbid MDD and hypertension on first episode CVD. 
Within this study, we look specifically at first-onset events, 
irrespective of whether they lead to death or not.
Hypertension is extremely common (affecting 1 billion 
people worldwide)8 and is responsible for 50% of all 
CVD.9 It is commonly comorbid with MDD,10 11 with recent 
meta-analysis showing 27% of individuals with hyperten-
sion having MDD12 and population-based studies showing 
a hypertension prevalence of 21% in those with MDD.11 
A biological link has been found by genome-wide associ-
ation studies, showing calcium-channel genes, important 
in blood pressure (BP) control and hypertension,13 also 
act to increase risk for MDD14 15 and bipolar disorder 
(BD).16 17 The sympathetic nervous system (SNS), renin–
angiotensin system, the immune system and the cortisol 
stress response system are all also implicated in both 
conditions.18 Medication management of both conditions 
are also thought to impact one another with side effects 
of psychotropic medications including raised BP and vice 
versa,19–21 although there is contrary evidence suggesting 
either medication or MDD may in actual fact be protec-
tive of hypertension.20 22
Here, we make use of prospective data from the UK 
Biobank cohort23 to test the hypothesis that a lifetime 
history of MDD in individuals with hypertension impacts 
adversely on first-episode CV events. We also assess 
whether MDD exacerbates the effects of hypertension as 
a risk factor for CVD.
MethODS
Study design
This was a population cohort study using data from UK 
Biobank. Four mutually exclusive groups (hypertension 
only, MDD only, hypertension plus MDD and a compar-
ison group) were compared for adverse CVD and stroke 
outcomes.
Sample description
UK Biobank is a large cohort of 502 655 participants 
recruited between April 2007 and July 2010 from 21 assess-
ment centres located across Great Britain.23 Participants 
aged 39–70 were invited to take participate if registered 
with the National Health Service (NHS) and lived within 
a reasonable distance of an assessment centre. At baseline 
assessment participants completed a series of detailed 
assessments relating to lifestyle and medical history on 
touchscreen questionnaire and have a range of physical 
health measurements, including body mass index (BMI) 
and BP taken by a nurse.
During the last 2 years of recruitment, questions relating 
to mood disorder features were added to the baseline 
assessment schedule questionnaire. From the 172 729 
participants asked these questions, 134 860 provided 
sufficient responses to be included in our analysis. 
Participants were excluded based on the following a 
priori criteria: a history of BD (n=1831) or schizophrenia 
(n=262); where there were insufficient data provided by 
participants to clearly rule out MDD (n=25 520) or hyper-
tension (n=1080); and where there were coding errors 
for date and/or time of death (n=4). These exclusions 
were based on self-report (individuals who listed schizo-
phrenia or BD from a list of pre-existing medical condi-
tions), or criteria for BD as per Smith et al,24 or where 
they responded ‘don’t know’ or ‘prefer not to answer’ 
to questions or data were missing that would limit our 
ability to exclude the presence of hypertension or MDD. 
Participants were further excluded from the adverse CVD 
outcome if they had a record of CVD prior to recruit-
ment (self-reported angina, myocardial infarction (MI) 
or stroke based on specific questions, or previous hospital 
admission for angina, MI or stroke) (n=9172). For the 
stroke outcome, this exclusion was limited to a record 
of stroke prior to baseline assessment (self-report or 
previous hospital admission for stroke) (n=2280).
Classification of hypertension and MDD
Participants were defined as having hypertension if either: 
(1) mean BP at baseline was greater than clinically defined 
criteria over two measurements (systolic BP greater than 
or equal to 140 mm Hg or diastolic BP greater than or 
equal to 90 mm Hg. Where only one reading was available 
this was used (n=1571)) or (2) self-reported ‘hyperten-
sion diagnosed by a doctor’ plus self-report of currently 
taking antihypertensive medication. This composite clas-
sification was used to ensure that undiagnosed hyperten-
sive participants were not misclassified and is in line with 
similar epidemiological studies.5 25 26 The requirement for 
antihypertensive use in the context of a history of hyper-
tension was incorporated to limit those on beta-blockers 
for anxiety. According to these criteria, n=68 964 partic-
ipants (51.1% of the sample) had hypertension for the 
adverse CV outcomes analysis and n=73 671 participants 
(52% of the sample) had hypertension in the stroke 
outcome analysis.
A history of lifetime MDD was defined according to 
the criteria for mood disorders developed by Smith et 
al24 27 and has been used in further papers27–31 (n=28 
027 adverse CV outcomes; n=29 528 stroke outcomes). 
Participants were classified as having a history of MDD 
if they reported at least one episode, which comprised 
depression and/or irritability, with a duration of at least 
2 weeks, plus had consulted with either a general practi-
tioner or psychiatrist for mental ill health. This classifica-
tion followed the structured diagnostic approach within 
the International Classification of Diseases (ICD)24 and is 
described in more detail within the online supplementary 
content.
For the adverse CV outcomes, the remainder of the 
samples with no history of hypertension or MDD (n=50 
798) were classified as a comparator group. The three 
mutually exclusive diagnostic groups for this study were, 
therefore, hypertension only (n=56 035); MDD only 
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(n=15 098) and hypertension plus MDD (n=12 929). For 
the stroke outcomes, the mutually exclusive groups were 
hypertension only (n=59 724); MDD only (n=15 581) and 
hypertension plus MDD (n=13 947) and no hyperten-
sion—no MDD (n=52 502).
Outcomes
The primary outcome was defined as a first-episode CV 
event leading to hospital admission or death, specifically 
angina, MI or chronic ischaemic heart disease (ICD-10 
codes I20–I259), and transient ischaemic attack or stroke 
(ICD-10 codes I60–69 and G45–G46). A secondary 
outcome was defined as stroke leading to hospital admis-
sion or death (ICD-10 codes I60–69 and G45–G46)32 due 
to the strength of relationship hypertension has with this 
outcome in particular.9 Admission data were obtained 
from Hospital Episode Statistics in England, Patient 
Episode Database for Wales and Scottish Morbidity 
Records in Scotland. Mortality outcomes were obtained 
from the NHS Information Centre for England and Wales 
and from the NHS Central Register for Scotland. Individ-
uals who died from a non-CV cause/stroke were censored 
at the time of death but not recorded as having an event. 
Admission data were available for Scottish, English and 
Welsh participants until 31 August 2014, 31 March 2015 
and 28 February 2015, respectively. End of follow-up was 
classified as these dates unless preceded by date of death 
or the date of first CV admission.
Confounding variables
Information on potential confounding factors was avail-
able for age, sex, socioeconomic status (Townsend 
score),33 self-reported ethnicity, age of leaving full-time 
education, diabetes, BMI, systolic BP, hypercholestero-
laemia, alcohol use, smoking history, sedentary behaviour 
(number of hours each day spent sitting at a computer, 
television or driving), physical activity levels34 and psycho-
tropic medication use. Specific details on these variables 
are provided in online supplementary content.
Analyses
Baseline characteristics were compared between groups 
using X2 tests for categorical variables and Kruskal-Wallis 
for continuous variables. Confounding variables were 
assessed for differences in adverse CV outcomes using log 
rank sums. For the four groups of interest, we assessed 
associations with adverse CV outcomes using Cox propor-
tional hazard regression and the Efron method for ties.35 
Models were applied in a staged process in line with 
previous studies3–5 and reported as unadjusted (model 1), 
partially adjusted (model 2) and fully adjusted (model 3). 
Model 2 adjusted for sociodemographic factors (age, sex, 
Townsend score, age of leaving full-time education and 
ethnicity) and model 3 additionally adjusted for health 
and lifestyle factors (diabetes, hypercholesterolaemia, 
BMI, smoking history, alcohol use, systolic BP, sedentary 
hours per day, physical activity and psychotropic medi-
cation use). The proportionality of hazard assumption 
was assessed using Schoenfeld residuals.36 We compared 
our fully adjusted models with results from competing 
risk analyses using the Fine and Gray approach,37 incor-
porating non-CV deaths as a competing event for CV 
events and non-stroke deaths for stroke events. The rela-
tive excess risk due to interaction (RERI)38 was calcu-
lated to assess for additivity in the risk. All analyses were 
performed with Stata statistical software, V.1239 with the 
exception of RERI which was calculated using the Micro-
soft Excel method of Andersson et al, which allows for 
comparison of adjusted outcomes.40 The presence of 
multiplicative interaction was calculated using the likeli-
hood ratio test.41
Psychotropic medication use was included as a 
confounding variable because of reports that they may 
increase risk of mortality42 but we also conducted a sensi-
tivity analysis which excluded participants who were 
taking psychotropic medication. Subgroup analyses 
looking separately at HRs in male and female groups 
only were also carried out to assess for any gender-specific 
differences in light of differing rates of depression and 
adverse CV events in each gender.24 43
time-varying coefficients
In the context of Schoenfeld residuals showing non-pro-
portionality, models with time-varying coefficients were 
used. In addition, log(-log) plots were carried out to find 
the time point at which the proportionality assumption 
failed. Following this, the data were stratified by time at 
this time point, effectively creating two separate survival 
analyses pre and post the failure time point.
Patient involvement
Although patients were not directly involved with the 
design of the specific research questions in this study, 
the hypotheses tested were developed in the context of 
clinical experience that depression and hypertension 
may interact to impact on CVD. UK Biobank has an 
active and ongoing programme of participant involve-
ment: www. ukbiobank. ac. uk/ participants/. The outcome 
measures used were those provided by the UK Biobank 
data collection protocol, the design of which had input 
from participants. UK Biobank also has a website and 
social media streams to disseminate research findings and 
hosts an annual scientific meeting, which includes cohort 
participants.
reSuLtS
The final sample for adverse CV outcome included 
134 860 participants, followed for a median duration 
of 63 months (702 901.6 person-years follow-up, mean 
62.5 months). In total 3685 (2.73%) participants had a 
first-episode CV event during the follow-up period (total 
number of all deaths plus non-fatal CV events=5788) 
and 910 (0.64%) participants had a first-episode stroke 
event (total number of all deaths plus non-fatal stroke 
events=7317).
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Table 1 describes the baseline characteristics of the four 
groups. In general, the hypertension only and comorbid 
hypertension plus MDD groups were older, had higher 
BMI and were more likely to have diabetes and hyper-
cholesterolaemia. The MDD only and comorbid hyper-
tension plus MDD groups had a higher proportion 
of women and were more likely to be current smokers 
(table 1). Gender-separated descriptive tables are shown 
in the online supplementary content (online supplemen-
tary tables 1 and 2).
The sample for stroke-specific outcomes included 141 
754 participants, followed for a median duration of 63 
months (735 247.7 person-years follow-up, mean 62.2 
months). Table 2 describes the baseline characteristics 
of the four groups, which display similar characteristics 
to the adverse CVD outcome groups. Gender-separated 
descriptive tables are shown in the online supplementary 
content (online supplementary tables 3 and 4).
Adverse CV outcomes
Within the main analysis and the female-only subgroup 
analysis, MDD failed the proportional hazards assump-
tion. Table 3 presents unadjusted and multivariate-ad-
justed HRs (aHRs) for adverse CV outcomes. In the fully 
adjusted model, relative to the comparator group, the 
aHR for adverse CV outcomes was significantly raised for 
hypertension only (aHR 1. 36, 95% CI 1.22 to 1.52) and 
higher still for comorbid hypertension plus MDD (aHR 
1.66, 95% CI 1.46 to 1.9) but reduced for MDD only (aHR 
0.55, 95% CI 0.46 to 0.76). Although the MDD only HR 
was noted to increase over time as a time-varying coeffi-
cient. With the exception of MDD, these findings were 
robust to sensitivity analysis excluding those on psycho-
tropic medication (sensitivity analysis aHR 1.43, 95% CI 
1.27 to 1.62; aHR 1.72, 95% CI 1.49 to 1.999, aHR 0.74, 
95% CI 0.52 to 1.06, respectively). Table 4 presents HRs 
and aHRs for adverse CV outcomes using the hyper-
tension only group as comparator. In the fully adjusted 
model, relative to hypertension, the aHR for adverse CV 
outcomes was significantly raised for comorbid hyperten-
sion plus MDD (aHR 1.22, 95% CI 1.1 to 1.35, sensitivity 
analysis aHR 1.20, 95% CI 1.08 to 1.34). An adjusted 
survival plot is shown in figure 1.
Within the subanalysis, the male-only model showed a 
significant increase in HR for hypertension (male aHR 
1.29, 95% CI 1.13 to 1.47) (online supplementary table 
5) and comorbid MDD and hypertension (male aHR 
1.47, 95% CI 1.24 to 1.74). However, the difference 
between comorbid disease and hypertension only was not 
statistically significant (aHR 1.14, 95% CI 0.995 to 1.3). 
The female-only subanalysis showed an increase in HR 
for hypertension (aHR 1.64, 95% CI 1.33 to 2.02) and 
a greater increase in comorbid MDD and hypertension 
(aHR 2.18, 95% CI 1.82 to 2.92) online supplementary 
table 6). The difference between comorbid disease and 
hypertension only was also statistically significant (aHR 
1.33, 95% CI 1.14 to 1.56). Sensitivity analysis supported 
these findings.
Stroke outcomes
None of the independent variables for stroke outcome 
failed the proportionality assumption. Table 5 presents 
HRs and aHRs for stroke outcomes. In the fully adjusted 
model, the aHR for stroke was insignificantly raised for 
hypertension only (aHR 1.21, 95% CI 0.97 to 1.51) and 
depression only (aHR 1.20, 95% CI 0.89 to 1.63) but 
significantly raised for comorbid hypertension plus MDD 
(aHR 1.37, 95% CI 1.04 to 1.79). In the hypertension 
comparator group, no group was significantly different 
from hypertension only (table 6). Similar trends were 
shown in the gender subset analysis but not reaching 
significance (online supplementary tables 7 and 8). An 
adjusted survival plot is shown in figure 2. Again, all 
results were supported by sensitivity analysis excluding 
those on psychotropic medication.
Interaction, time-stratified analysis and competing risk 
analysis
Survival analysis stratified by time is described and 
included within the online supplementary content (online 
supplementary tables 9 and 10 and figure 3). There was 
evidence of both additive and multiplicative interaction 
between hypertension and MDD at baseline for the overall 
CV outcome analysis before the 22.5-month time point 
(additive: RERI 0.563, 95% CI 0.189 to 0.938. Multiplica-
tive: likelihood ratio p=value 0.0116) and the female-only 
CV endpoint analysis before the 29-month time point 
(additive: RERI 0.588, 95% CI 0.074 to 1.103. Multiplica-
tive: likelihood ratio p value 0.031). However, after these 
time points, there was no evidence of interaction on either 
the additive or multiplicative scale. Online supplementary 
table 11 shows the full results for this analysis. Competing 
risk analysis showed no significant difference from the main 
analyses for CV outcomes or stroke outcomes (tables 7–8).
DISCuSSIOn
In this large population cohort of middle-aged adults 
without CVD (adjusted for a broad range of confounders), 
individuals with comorbid hypertension and MDD were 
at increased risk of CVD when compared with those with 
hypertension alone, MDD alone and neither condition. 
There was some evidence of additive and multiplicative 
interaction between hypertension and MDD at baseline, 
but not throughout follow-up and only within the female 
subgroup. Such a finding may suggest a causal interac-
tion between MDD and hypertension in females only, 
but suggests that this may be limited over time leading 
to a suspected further interaction with a gender-specific 
unmeasured confounder. Differences between comorbid 
disease and either disease alone or no disease were more 
marked in females. For stroke outcomes, comorbid 
depression and hypertension was the only group that 
showed significantly increased HRs.
Previous research
Our findings expand on previous research from UK 
Biobank looking at CVD in those with BD and MDD.27 
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It was found that there were significantly increased odds 
of having ‘any CVD’ (fully adjusted OR 1.15, 95% CI 
1.12 to 1.19) or hypertension (fully adjusted OR 1.15, 
95% CI 1.13 to 1.18) if depressed, with even higher odds 
for stroke (fully adjusted OR 1.26, 95% CI 1.13 to 1.40). 
There are distinct differences between our current paper 
and the previous publication. Follow-up data within UK 
Biobank have been released to allow meaningful prospec-
tive studies be conducted. Thus, the current paper has 
the benefits of using hospital records and death certifica-
tion for outcomes, rather than self-reported data. We are 
also able to make inferences about the direction of effect 
regarding MDD and CVD and assess the influence of 
hypertension and MDD over time, both in isolation and 
when comorbid, and assess for statistical interaction to 
inform on whether there may be a biological interaction.
Other survival analyses in hypertension/MDD comor-
bidity have focused primarily on mortality outcomes. 
In the National Health and Nutrition Epidemiologic 
Follow-up Study in the 31USA and the Taiwanese Survey of 
Health and Living Status,32 individuals with self-reported 
hypertension plus depressive symptoms (compared with 
a reference group with neither) had increased all-cause 
mortality (aHR 1.39, 95% CI 1.14 to 1.69, aHR 1.54, 
95% CI 1.29 to 1.83, respectively)3 4 with the former also 
showing increased CVD-specific mortality (aHR 1.59, 
95% CI 1.08 to 2.34).4 Similarly, Hamer et al5 reported 
a prospective analysis of common mental disorder on 
mortality outcomes in individuals with hypertension 
versus those without hypertension in participants from 
the Health Survey for England and the Scottish Health 
Survey (1994–2004), finding that risk of CVD death was 
highest in the group with comorbid disease.
Strengths
These observations are broadly consistent with our results 
but our study has a number of methodological advan-
tages, including a very large sample size, adjustment of 
analyses for a more comprehensive range of confounders 
and a focus on first-episode non-fatal and fatal adverse 
CV events. We also used a definition of prior MDD history 
which was based on diagnostic criteria within ICD-10 
(rather than a threshold score on a depressive symptoms 
or general well-being scale) and our composite definition 
of hypertension incorporated history, baseline medica-
tion and BP measurements. Lifetime MDD is thought 
to be under-reported in the literature. However, using 
current symptom scores may reduce power and preci-
sion because a smaller number of respondents would be 
identified as having an episode of MDD.44 Given that we 
are assessing outcomes for which risk accumulates over a 
lifetime, we felt that a primary focus on lifetime episodes 
was appropriate. We believe our lifetime definition to be 
better suited as it offers a view depression and depressive 
symptoms over the course of a lifespan as opposed the 
past week. Also, within our current study, we were able 
to exclude those with previous self-declared or hospital 
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Table 2 Baseline characteristics for stroke outcomes
Comparator group Hypertension only MDD only Hypertension plus MDD
n=52 502 n=59 724 n=15 581 n=13 947
Median age (range)* 54 (47–61) 61 (55–65) 54 (47–61) 60 (53–64)
Females, N (%) 29 684 (56.54) 26 937 (45.1) 11 143 (71.52) 8090 (58.01)
Ethnicity, N (%)
  White 47 697 (90.85) 54 578 (91.38) 14 697 (94.33) 13 212 (94.73)
  Asian/Asian British 1857 (3.54) 1889 (3.16) 280 (1.8) 209 (1.5)
  Black/ Black British 1355 (2.58) 1854 (3.1) 223 (1.43) 246 (1.76)
Median Townsend score 
(range)*
−1.89 (−3.45 to 0.55) −2.04 (−3.49 to 0.44) −1.56 (−3.28 to 1.15) −1.74 (−3.4 to 0.93)
Age at leaving full-time education, N (%)
  <16 6446 (12.28) 13 396 (22.43) 1884 (12.09) 2945 (21.12)
  16 10 590 (20.17) 12 507 (20.94) 3270 (20.99) 2953 (21.17)
  >16 34 914 (66.5) 33 114 (55.45) 10 317 (66.22) 7947 (56.98)
Total physical activity in 
metabolic
3.96 (1.67–8.02) 3.75 (1.5–8) 4.13 (1.67–8.36) 3.66 (1.45–7.83)
Sedentary time in hours, 
median (range)*
4 (3–6) 5 (3.5–6) 5 (3.5–6.5) 5 (4–7)
Diabetes, N (%) 1454 (2.77) 4502 (7.54) 449 (2.88) 1163 (8.34)
Hypercholesterolaemia, 
N (%)
3592 (6.84) 10 768 (18.03) 1049 (6.73) 2620 (18.79)
Systolic BP in mm Hg, 
median (range)*
125.5 (118–132) 149.5 (142–159.5) 127 (120.5–133) 147.5 (140.5–156.5)
Body mass index (kg/m2), N (%)
  <18.5 395 (0.75) 151 (0.25) 104 (0.67) 38 (0.27)
  18.5–25 22 967 (43.75) 14 242 (23.85) 6374 (40.91) 3017 (21.63)
  25–30 21 185 (40.35) 26 817 (44.9) 6149 (39.46) 5769 (41.36)
  >30 7953 (15.15) 18 514 (31) 2954 (18.96) 5123 (36.73)
Smoking status, N (%)
  Never smoked 31 318 (59.65) 32 982 (55.22) 8052 (51.68) 6834 (49)
  Previously smoked 15 851 (30.19) 22 019 (36.87) 5340 (34.27) 5560 (39.87)
  Current smoker 5170 (9.85) 4501 (7.54) 2163 (13.88) 1519 (10.89)
Alcohol frequency, N (%)
  Daily or almost daily 9760 (18.59) 13 751 (23.02) 2817 (18.08) 3085 (22.12)
  Three or four times a 
week
12 563 (23.93) 13 827 (23.15) 3335 (21.4) 3020 (21.65)
  Once or twice a week 14 089 (26.84) 14 719 (24.65) 3993 (25.63) 3125 (22.41)
  One to three times a 
month
6220 (11.85) 5971 (10) 2122 (13.62) 1627 (11.67)
  Special occasions only 5744 (10.94) 6794 (11.38) 1978 (12.69) 1885 (13.52)
  Never 4102 (7.81) 4630 (7.75) 1330 (8.54 1199 (8.6)
Psychotropic medication, 
N (%)
1408 (2.68) 1996 (3.34) 2976 (19.1) 2778 (19.92)
All data presented as N (%) and has X2 p <0.001 except * which are median values (IQR) and have a Kruskal-Wallis p of 
0.0001. Data presented as MET-hours (metabolic equivalents: hours per week spent doing exercise adjusted for multiples 
of basal metabolic rate in accordance with International Physical Activity Questionnaire). Townsend score is an area based 
measure based on census statistics. It is a calculation based on the number of: households without a car, overcrowded 
households, households not owner occupied and unemployment.
BP, blood pressure; MDD, major depressive disorder.
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Figure 1 Adjusted survival analysis graph for adverse 
cardiovascular outcome showing greatest hazard for the 
comorbid group. MDD appears protective compared with the 
comparator group initially, however, shows increased hazard 
after 41 months. Analysis adjusted for age, sex, Townsend 
score, age of leaving full-time education and ethnicity, history 
of diabetes, history of hypercholesterolaemia, BMI, smoking 
history, alcohol use, systolic blood pressure, sedentary hours 
per day, physical activity and psychotropic medication use. 
BMI, body mass index; MDD, major depressive disorder.
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admission CVD, as previous studies show depression may 
result from CVD45 46 and worsen prognosis.46
Limitations
However, some limitations are acknowledged. Recruit-
ment criteria for UK Biobank may lead to selection bias. 
Specifically, age restrictions may lead to under-represen-
tation of early-onset hypertension and those with more 
severe MDD may be less inclined to attend for assessment. 
We also acknowledge limitations with our classifications 
of MDD and hypertension, which were primarily self-re-
port rather than formal diagnostic assessments. Although 
we have excluded prior CV events where possible, the 
MDD plus hypertension subtype may capture older indi-
viduals with a degree of vascular depression, which has 
an established association with raised BP.47 In addition, 
although we adjust for a host of risk factors at baseline 
such as smoking status, BMI and psychotropic medica-
tion, we are limited by the lack of follow-up data, which 
could show change and modification of said risk factors 
over time. Similarly, we were unable to assess for medi-
cation adherence and transitions from one investigatory 
group to another. Participants who are aware of or had 
sought treatment for MDD may also have complicated our 
findings, however, our sensitivity analysis excluded those 
using pharmaceutical treatments and was in keeping with 
our main findings. Such modifications could explain 
the non-proportional nature of the depression group, 
which may in itself be a predictor of poor medication 
adherence.48 Although adherence to medication was not 
formally assessed, the number and duration of antihyper-
tensive medications used in the hypertension plus MDD 
group was the same as for the hypertension only group 
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Figure 2 Adjusted survival analysis graph for stroke 
outcomes showing significantly increased hazard for 
comorbid hypertension and MDD, with similar insignificant 
increased hazard trends for hypertension only and MDD 
only. analysis adjusted for age, sex, Townsend score, age of 
leaving full-time education and ethnicity, history of diabetes, 
history of hypercholesterolaemia, BMI, smoking history, 
alcohol use, systolic blood pressure, sedentary hours per 
day, physical activity and psychotropic medication use. BMI, 
body mass index; MDD, major depressive disorder.
Figure 3 Log (-log) plot showing non-proportionality of 
MDD only survival over time. Paths between the comparator 
group and the MDD group cross at the 22.5 months mark. 
Analysis adjusted for age, sex, Townsend score, age of 
leaving full-time education and ethnicity, history of diabetes, 
history of hypercholesterolaemia, BMI, smoking history, 
alcohol use, systolic blood pressure, sedentary hours per 
day, physical activity and psychotropic medication use. BMI, 
body mass index; MDD, major depressive disorder.
(online supplementary content, online supplementary 
table 12). As such, worse outcomes in the MDD plus 
hypertension group are not explained by less intensive 
antihypertensive treatment at baseline. The endpoints 
used for stroke and CV events also require to be further 
validated, however, are in line with previous epidemi-
ological studies5 and have been suggested in previous 
papers in UK Biobank.32 CV endpoints have not, to our 
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Table 7 Fully adjusted HR compared with results from competing risks analysis for cardiovascular endpoints
Fully adjusted non-competing risks analysis Fully adjusted competing risks model
aHR 95% CI P value aHR 95% CI P value
Group
  No hypertension—no MDD 1(ref)     1(ref)     
  Hypertension only 1.36 (1.22 to 1.52) 2.92×10−8 1.37 (1.22 to 1.53) 4×10−8
  MDD only 0.75 (0.54 to 1.04) 0.08 0.76 (0.55 to 1.03) 0.08
  Hypertension and MDD 1.66 (1.45 to 1.9) 7.48×10−14 1.67 (1.45 to 1.91) 2.2×10−13
Tvc             
  MDD only 1.01 (1.004 to 1.02) 3.03×10–3 1.01 (1.004 to 1.02) 0.003
Adjusted for age, sex, Townsend score, age of leaving full-time education and ethnicity, history of diabetes, history of hypercholesterolaemia, 
BMI, smoking history, alcohol use, systolic blood pressure, sedentary hours per day, physical activity and psychotropic medication use.
aHR, adjusted HR; BMI, body mass index; MDD, major depressive disorder.
Table 8 Fully adjusted HR compared with results from competing risks analysis for stroke endpoints
Group
Fully adjusted non-competing risks analysis Fully adjusted competing risks model
aHR 95% CI P value aHR 95% CI P value
No hypertension—no MDD 1(ref)     1(ref)     
Hypertension only 1.21 (0.97 to 1.51) 0.09 1.21 (0.96 to 1.52) 0.1
MDD only 1.20 (0.89 to 1.63) 0.24 1.20 (0.88 to 1.64) 0.25
Hypertension and MDD 1.37 (1.04 to 1.79) 0.02 1.36 (1.03 to 1.8) 0.031
Adjusted for age, sex, Townsend score, age of leaving full-time education and ethnicity, history of diabetes, history of hypercholesterolaemia, 
BMI, smoking history, alcohol use, systolic blood pressure, sedentary hours per day, physical activity and psychotropic medication use.
aHR, adjusted HR; BMI, body mass index; MDD, major depressive disorder.
knowledge, been validated within UK Biobank, however, 
we do not feel that this will bias the results towards any 
particular group. The amelioration of the aHR suggests 
other covariates contribute considerably to the risk. This 
is important in the context of increased rates of diabetes, 
hypercholesterolaemia and obesity along with lower socio-
economic status in the hypertension only and comorbid 
groups and as such we may be seeing the summation of 
CV risk factors. Finally, the overall recruitment rate to UK 
Biobank was low (at around 6%); however, the large final 
cohort size, the depth and diversity of phenotype data 
collected at baseline and the wide sociodemographic 
representation of participants all make our findings 
highly relevant to UK primary care settings. While UK 
Biobank participants cannot be used to provide represen-
tative disease prevalence and incidence rates, valid assess-
ment of exposure–disease relationships are nonetheless 
widely generalisable and do not require participants to be 
representative of the UK population at large,49 although 
findings will not be generalisable to other countries.
Possible mechanisms
Our finding that a history of MDD, in the context of a 
current diagnosis of hypertension increased the risk of 
first-episode CVD, is complicated by the time-varying risk 
that MDD conveys to CVD. Subsample analysis show this 
time-varying aspect is gender specific to females. Within 
our sample, the MDD group has a slightly reduced BP 
compared with comparators. Previously, reduced BP has 
been put forth as being causative of MDD and therefore 
reducing CVD risk,20 but findings from longitudinal studies 
are inconsistent with regard to direction of effect.50 51 
Potential menopausal effects are tempting explanations. 
Common factors for BP and mood such as neuropep-
tide Y52 53 may also influence CV outcomes. Neuropep-
tide Y is linked tovasoconstriction and down-regulated by 
oestrogen54 . Neuropeptide Y and oestrogen may repre-
sent a biologically plausible interaction between MDD and 
hypertension, however, this would require investigation.
Personality factors may also play a role. MDD correlates 
highly with neuroticism which, although inconsistent, 
may be protective of CVD.56 Conscientiousness traits 
may lead to better outcomes57 and it is possible that this 
trait has been selected for within UK Biobank. Despite 
this early reduced risk, due to the time-varying nature of 
MDD, MDD has increased risk in the latter aspects of the 
time-stratified analyses for the full and female-only anal-
yses (online supplementary tables 9 and 10). The findings 
from our study in this context suggest that MDDs role as 
a risk factor for CVD and its relationship with BP may be 
much more complex than initially thought, in particular 
within female populations; however, further investigation 
is clearly needed.
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We can see in the hypertension-only baseline models 
that comorbid hypertension and depression convey a 
significantly greater risk than hypertension alone. Indi-
viduals with either hypertension or depression may 
have increased sympathetic stimulation that is increased 
further in comorbid states leading to worse outcomes.58
COnCLuSIOnS
Overall, our findings may have important implications 
for routine clinical practice, particularly within primary 
care settings and further demonstrate the complex rela-
tionship between depression and hypertension. Although 
evidence of an interaction is inconsistent, we found 
that comorbid hypertension and depression conferred 
greater hazard than hypertension alone for adverse CV 
outcomes. This significant finding remained after adjust-
ment for factors such as BMI, smoking status and diabetes 
and was robust to sensitivity analysis excluding those on 
psychotropic medication. One implication is that clini-
cians should be more aware of the negative long-term 
impact on CVD outcomes caused by a history of MDD in 
the context of hypertension, particularly within females. 
Although this work awaits replication and testing in other 
cohorts and settings, further work in this field may suggest 
that future iterations of CVD risk prediction tools, such as 
ASSIGN,59 would benefit from the addition of a question 
on whether individuals have a history of MDD, to facili-
tate more intensive support to prevent CVD.60
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